Pharmaceuticals: Why ad spending’s ailing
March 28, 2013
A number of ad categories have increased spending over the past few years following deep declines during the height of the recession.
Pharmaceuticals is not one of them.
Even as positive economic news builds, including a decrease in the unemployment rate, an increase in home building starts and a surge in the stock market, drug companies have reigned in their ad budgets.
Unlike many other categories, such as automotive and retail, pharmaceutical spending is tied not so much to the economy as to the state of the industry itself, and right now the mood is one of extreme caution.
Last year GlaxoKlineSmith reached a $3 billion settlement with the Justice Department over the marketing and development of its drugs. The government accused the British company of, among other things, advertising its drugs to treat ailments they were not approved for.
“Overall the business in the past several years has taken a more cautious approach to marketing in response to fears about regulation,” notes Jon Swallen, chief research officer at Kantar Media North America.
No one wants to be the next GlaxoKlineSmith, and in response many companies have pulled back on their advertising.
Last year spending in the category declined 3.8 percent, according to data crunched by Kantar and Nomura, from $7.6 billion to $7.31 billion.
It was the third-biggest decline for any top-20 ad category, behind only office supplies (down 10.3 percent) and media and entertainment (down 4.2 percent).
No individual pharmaceutical advertiser finished among the top 10 for 2012, according to Kantar. Pfizer was among the top seven until 2011.
Pharmaceutical advertising has dropped sharply in magazines as well as spot television, where spending plunged 30 percent last year, according to the TVB.
The other issue holding back spending is that there hasn’t been a major new drug introduction in some years. With no major new drugs to promote, pharmaceutical companies have little reason to increase spending.
In the past, rollouts of drugs such as Viagra, Lipitor and Zoloft have triggered a huge amount of ad spending to familiarize the public with the purpose and benefits of the new medications.
“Part of the reason is there have not been any big blockbuster marketing launches for newly approved drugs,” Swallen says.
“That was traditionally the catalyst during the last half of the past decade, 2005 to 2010. The category was propelled by marketing introductions.”
And with no major introductions on the horizon, the pharmaceutical ad chill could last for years to come.
After nearly 18 years, it’s time to say good-bye
Yet more evidence native advertising doesn’t work
A new type of cord-cutting: Snipping broadband
Coming, the collapse of radio’s iHeartMedia
Weeklies: Surviving if not thriving in digital age
Tweeter in chief: How Trump could save Twitter
Shows Trump hates are seeing big ad gains
Broadcast vs. cable: How the top shows stack up
A sign that coughs at your cigarette smoke
The word: Time Inc. sale is imminent
Rundown: Which advertisers have jumped from YouTube
Media Life’s Digital Media Transparency Initiative
HBO does hard time with Dwayne Johnson
- Arun Kumar becomes chief data and marketing tech officer at IPG
- Jenny Campbell rises to managing director at 72andSunny
- Adam Crandall becomes director of strategy at mono
- Mark Wildman rises to EVP of partnerships at Westwood One
- Kevin Craig rises to SVP of newspaper relations at AMG/Parade
- Bill Corvalan becomes VP of West Coast partnerships at AllOver Media
- Richard Just becomes editor at The Washington Post Magazine
- Gemma Lawson rises to VP and design director at Nickelodeon
- Ashley Judd joins Epix' 'Berlin Station'
- Former NBC ad sales executive Robert Blackmore dies at age 90
This week’s broadcast ratings
This week’s cable ratings
This week’s top-rated movies, songs and books
This week’s daypart ratings
This month’s digital traffic data: December 2016
Ad sales rep for a digital-only magazine
Freelance media planner/buyer available for all markets
Wanted: Media buyer in Philadelphia
Paid social media planner wanted in Detroit
Opening for a media planner at a top OOH agency